[Dynamics of serum IL-17A, IL-17F and IL-23 in patients with inflammatory bowel disease].
The analysis of the levels of proinflammatory cytokines IL-17A, IL-17F and IL-23 allow to evaluate the effectiveness of the therapy:, so MSCs systemic immunosuppressive therapy and corticosteroids increasingly reduces the level of all studied proinflammatory cytokines, while in therapy with infliximab, a selective immunosuppressive agent, significantly less effect on the level of proinflammatory cytokines IL-17A, IL-17F and IL-23.
L B
LB
Lazebnik
V É
VÉ
Sagynbaeva
O V
OV
Kniazev
I N
IN
Ruchkina
L I
LI
Efremov
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D015212:Inflammatory Bowel Diseases / Q000097:blood* / Q000188:drug therapy / Q000276:immunology; D000069285:Infliximab; D020381:Interleukin-17 / Q000097:blood* / Q000276:immunology; D053759:Interleukin-23 / Q000097:blood* / Q000276:immunology; D008297:Male; D008875:Middle Aged
D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; C508717:IL17A protein, human; C440021:IL17F protein, human; D007166:Immunosuppressive Agents; D020381:Interleukin-17; D053759:Interleukin-23; D000069285:Infliximab